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Abstract
Syndecan-1 is a transmembrane heparan sulfate-bearing proteoglycan known to regulate multiple biological functions at
the cell surface and within the extracellular matrix. Its functional activity can be modulated by heparanase, an enzyme that
cleaves heparan sulfate chains and whose expression has been associated with an aggressive phenotype in many cancers. In
addition to remodeling syndecan-1 by cleaving its heparan sulfate chains, heparanase influences syndecan-1 location by
upregulating expression of enzymes that accelerate its shedding from the cell surface. In the present study we discovered
that heparanase also alters the level of nuclear syndecan-1. Upon upregulation of heparanase expression or following
addition of recombinant heparanase to myeloma cells, the nuclear localization of syndecan-1 drops dramatically as revealed
by confocal microscopy, western blotting and quantification by ELISA. This effect requires enzymatically active heparanase
because cells expressing high levels of mutated, enzymatically inactive heparanase, failed to diminish syndecan-1 levels in
the nucleus. Although heparan sulfate function within the nucleus is not well understood, there is emerging evidence that it
may act to repress transcriptional activity. The resulting changes in gene expression facilitated by the loss of nuclear
syndecan-1 could explain how heparanase enhances expression of MMP-9, VEGF, tissue factor and perhaps other effectors
that condition the tumor microenvironment to promote an aggressive cancer phenotype.
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Introduction
Heparanase is an enzyme known to promote the progression of
many cancers [1]. Its tumor promoting effects are due to
enzymatic degradation of heparan sulfate that can, for example,
liberate heparin-binding growth factors and remodel the extracel-
lular matrix to facilitate tumor metastasis. In addition, via both
enzymatic and non-enzymatic activities, heparanase can alter cell
signaling with downstream effects on gene transcription [2]. Thus,
heparanase is a multifunctional effector molecule whose complete
repertoire of functions is still being elucidated.
It was recently discovered that heparanase can also enhance
shedding of the syndecan-1 heparan sulfate proteoglycan from the
surface of tumor cells [3,4]. This occurs through heparanase-
mediated upregulation of ERK phosphorylation leading to
enhanced expression of MMP-9, a syndecan-1 sheddase [5]. The
enhanced shedding of syndecan-1 is important biologically,
because the shed proteoglycan remains active and can influence
a wide array of behaviors such as tumor growth and metastasis,
chemokine localization, leukocyte trafficking and pathogen
virulence [6,7,8]. Thus, the change in location of syndecan-1
from the cell surface to the extracellular compartment has distinct
and important pathological consequences.
Although heparan sulfate proteoglycans on the cell surface and
within the extracellular matrix have been studied extensively, much
less is known about their expression and function in the nucleus of
cells. There are reports that syndecan-1 and other heparan sulfate
proteoglycans are present in the nucleus [9,10,11,12,13]. The role
of heparan sulfate in the nucleus has been linked to control of cell
proliferation, shuttling of the heparin-binding growth factor FGF2,
inhibition of DNA topoisomerase I activity and stabilization of the
mitotic machinery [11,12,14,15,16]. The finding that heparan
sulfate can inhibit DNA topoisomerase I activity suggests that its
presence in the nucleus may inhibit gene transcription [15]. In
addition, a recent study demonstrated that glycosaminoglycans,
including heparin and heparan sulfate, can inhibit histone
acetyltransferase (HAT) [17]. Because HAT facilitates transcrip-
tional activation, these results also point to nuclear heparan sulfate
as a repressor of gene transcription. This may be particularly
importantinpathologicalsituationssuchascancer,whereabnormal
HAT activity has been detected [18].
Given that heparanase promotes an aggressive tumor phenotype
and that it can also regulate the location of syndecan-1, we
examined the effect of heparanase expression on syndecan-1
localization within the nucleus. By confocal microscopy, western
blotting and ELISA assay we demonstrate that when heparanase
expression is increased in a human myeloma cell line, the level of
syndecan-1 in the nucleus decreases dramatically. This ability of
heparanase to regulate nuclear syndecan-1 may represent a
mechanism whereby heparanase influences gene transcription with
downstream effects that promote the aggressive tumor phenotype.
Results
Using confocal microscopy we noted that syndecan-1 was
localized within the nucleus of CAG myeloma cells expressing low
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nucleus of CAG cells expressing high levels of heparanase (HPSE-
high cells) (Fig. 1). Cytoplasmic staining for syndecan-1 was
present in both HPSE-low and HPSE-high cells but was more
prominent in the HPSE-low cells. Both HPSE-low and HPSE-high
cells exhibited bright staining on the cell surface, often in patches
(Fig. 1). This cell surface pattern of staining is consistent with our
previous finding that syndecan-1 is often found concentrated on
uropods, structures present at the trailing edge of motile cells [19].
To examine further the nuclear localization of syndecan-1, cells
were extracted and nuclear and non-nuclear fractions were
isolated. (Although most studies refer to these as nuclear and
cytoplasmic fractions, we use the terms nuclear and non-nuclear
because the non-nuclear fraction includes not only cytoplasmic
molecules but also cell surface molecules.) Western blots detected
abundant syndecan-1 within the nuclear fraction of the HPSE-low
cells but none within the nuclear fraction of the HPSE-high cells
(Fig. 2A). Syndecan-1 is detected as a smear on western blots due
to its heterogeneity in molecular size because of variations in
glycosaminoglycan chain size and number [20]. As we have
previously described, the size of syndecan-1 isolated from the
HPSE-high cells is smaller than that from the HPSE-low cells due
to heparanase cleavage of the heparan sulfate chains [21].
Immunostaining of the same blot with antibodies to heparanase
revealed elevated levels of the 65 kDa (latent) and 52 kDa (active)
enzyme were present in the nuclear and non-nuclear fractions of
the HPSE-high cells as compared to HPSE-low cells. Detection of
heparanase in the nucleus is consistent with previous reports [22].
Although not evident in this blot, our previous characterizations
have revealed that low levels of heparanase are expressed by the
HPSE-low cells [21]. Staining of the blot for SP1 and actin
confirmed the fidelity of the nuclear and non-nuclear fractions,
respectively (Fig. 2A). Interestingly, we found that SP1 levels were
consistently lower in western blots of nuclear fractions of HPSE-
high cells as compared to HPSE-low cells. This occurred even
when the HPSE-high cells were expressing the mutated,
enzymatically inactive form of the enzyme (data not shown). This
raises the possibility that heparanase may be regulating levels of
SP1 within the nucleus.
To ensure that the result above was not due to an artifact of
the cell transfection process, we examined CAG cells that had
been transfected with the cDNA for heparanase utilizing a
different expression vector (pIRES2). In addition, as an
alternative to assessing the fractions by Western blotting, the
levels of syndecan-1 in the nuclear and non-nuclear fractions
were quantified by ELISA. Results confirm the syndecan-1 levels
in the nucleus drop dramatically when high levels of heparanase
are expressed by these cells (Fig. 2B). In addition, shRNA
knockdown of the endogenous expression of heparanase in wild-
type CAG cells resulted in elevation of syndecan-1 levels in the
nucleus (Fig. 2B). Not surprisingly, this increase in nuclear
syndecan-1 was accompanied by a decrease in non-nuclear
syndecan-1. This could be due to redistribution of non-nuclear
syndecan-1 into the nucleus and/or due to an overall decrease in
syndecan-1 expression upon heparanase knockdown [3]. To-
gether these data reveal that the level of nuclear syndecan-1 in
these cells correlates inversely with levels of heparanase
expression.
Because heparanase can have biological functions that are
independent of its heparan sulfate degrading activity [1], we also
examined nuclear syndecan-1 levels in cells transfected with
mutated heparanase that lacks enzyme activity. Cells expressing
these mutated forms of heparanase retained substantial nuclear
syndecan-1 as compared to cells expressing the active enzyme
(Fig. 3). This indicates that the regulation of syndecan-1 level in
the nucleus is dependent, at least in part, on the heparan sulfate
degrading activity of heparanase. In addition, cells transfected with
the cDNA for the mutated enzyme act as an additional negative
control for these studies because in each of the two mutation
constructs only a single amino acid is altered, yet nuclear
syndecan-1 levels are retained [3,23].
Lastly, as a final confirmation of the effect of heparanase on
nuclear syndecan-1 levels, exogenous heparanase was added to
cells expressing very low levels of heparanase (heparanase
knockdown cells). These experiments were feasible due to the
ability of cells, including the CAG cells, to take up and utilize
exogenously added heparanase [3,24,25]. In response to
recombinant heparanase, the level of syndecan-1 present in
Figure 1. Syndecan-1 is not detected within the nucleus of cells expressing high levels of heparanase. Confocal microscopic z-stack
images of (A) HPSE-low and (B) HPSE-high cells immunostained using antibody to syndecan-1. Blue (Hoechst stain) identifies nuclei; white identifies
syndecan-1 within the nucleus (co-localization of Hoechst and syndecan-1); green identifies cytoplasmic and cell surface syndecan-1. Syndecan-1 is
detected within nuclei of HPSE-low cells but absent in nuclei of the HPSE-high cells. Bar=10 mm. Note: As is characteristic of myeloma cells, the size
of the nucleus is large relative to the amount of cytoplasm.
doi:10.1371/journal.pone.0004947.g001
Nuclear Syndecan-1
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(Fig. 4). This confirms results obtained with heparanase
transfected cells and strengthens the conclusion that heparanase
regulates levels of syndecan-1 in the nucleus. Moreover, the
finding that addition of exogenous heparanase can affect nuclear
syndecan-1 levels indicates that the level of syndecan-1 in the
nucleus of one cell can be altered by uptake of heparanase that
was produced by another cell. Thus, heparanase may influence
the nuclear localization of syndecan-1 broadly throughout the
tumor microenvironment, even within cells lacking heparanase
expression.
Discussion
This work reveals that heparanase regulates the level of
syndecan-1 present in the nucleus. This was demonstrated by
showing that upregulation of heparanase caused decreased
amounts of nuclear syndecan-1 using i) confocal microscopy, ii)
Western blotting of nuclear and non-nuclear extracts, and iii)
ELISA assays to quantify the amount of syndecan-1 present in
nuclear and non-nuclear fractions. Upregulation of heparanase
was achieved by either transfection with the cDNA for human
heparanase into cells (using two different vectors) or by addition of
exogenous heparanase to cells. In addition, cells expressing
mutated heparanase lacking enzymatic activity retained high
levels of nuclear syndecan-1 demonstrating that only the active
form of the enzyme diminishes levels of nuclear syndecan-1.
Although heparan sulfate proteoglycans have been found within
the nucleus, there are only limited reports regarding nuclear
syndecan-1 [12,16]. Syndecan-1 has not been previously reported
to be localized in the nucleus of myeloma cells or in myeloma
patient tumor cell samples. However, staining of bone marrow
biopsies for syndecan-1 often includes counterstaining of nuclei
which may prohibit detection of nuclear syndecan-1. In two
reports, close scrutiny of biopsies stained with antibodies to
Figure 2. Elevated expression of heparanase dramatically
decreases the level of syndecan-1 present within the nucleus.
A) Nuclear and non-nuclear fractions were isolated from HPSE-low and
HPSE-high cells (prepared using the pcDNA3 vector for transfections)
and separated on SDS-PAGE. Western blots were probed with antibody
to human syndecan-1, human heparanase, SP-1 or actin. B) Nuclear and
non-nuclear fractions were isolated from HPSE-low and HPSE-high cells
(prepared using the pIRES2 vector for transfections) and from wild-type
CAG cells infected with control shRNA or an shRNA targeting
heparanase. The quantity of syndecan-1 in each fraction was
determined by ELISA. Grey bars=non-nuclear fraction; Black bars=
nuclear fraction. Error bars represent standard error of the mean.
*, P,0.01 vs. nuclear syndecan-1 in HPSE low cells; **, P,0.02 vs.
nuclear syndecan-1 in shRNA control.
doi:10.1371/journal.pone.0004947.g002
Figure 3. Heparanase enzymatic activity is required for
reduction of syndecan-1 levels in the nucleus. Nuclear and non-
nuclear fractions were prepared from CAG cells expressing high levels
of wild-type heparanase (HPSE-high) or heparanase mutated at either
amino acid 343 (M343) or amino acid 225 (M225) which renders them
enzymatically inactive. All cells were prepared using pIRES2 vectors for
transfections. Fractions were analyzed for syndecan-1 levels by A)
western blotting and B) ELISA. Grey bars=non-nuclear fraction; Black
bars=nuclear fraction. Error bars represent standard error of the mean.
*, P,0.01 vs. nuclear syndecan-1 in HPSE high cells.
doi:10.1371/journal.pone.0004947.g003
Nuclear Syndecan-1
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syndecan-1 within the nucleus may not be assessable to antibody
and thus not easily detected. This possibility is supported by our
data in the present study where only moderate levels of syndecan-1
in the nucleus were detected in the heparanase-low cells by
confocal microscopy, but in contrast, high levels of syndecan-1
were detected in the nuclear fraction of these cells by both western
blotting and ELISA.
We do not yet know the mechanism whereby heparanase
regulates the level of nuclear syndecan-1. Syndecan-1 lacks a
nuclear localization signal [28] and thus may require a binding
partner to shuttle it into the nucleus. Heparanase could influence
the expression or function of this binding partner or, conversely,
trimming of heparan sulfate chains by heparanase may render it no
longer interactive with the shuttling molecule. Yet another
possibility is that the onset of increased shedding of syndecan-1
caused by heparanase expression [3] results in more syndecan-1
being transported to the cell surface thereby making less available
for nuclear transport. These possibilities await further investigation.
Heparanase expression has been linked to enhanced tumor
aggressive behavior and poor prognosis in a number of cancers [1].
This role of heparanase is supported by findings that heparanase
inhibitors can inhibit tumor growth and metastasis [29,30,31].
Heparanase can facilitate breakdown of the extracellular matrix
which aids tumor cell migration and releases factors that promote
tumor growth, angiogenesis and metastasis [1]. Additionally, there
is growing evidence that heparanase can upregulate expression of
genes that participate in creating aggressive behavior of tumors.
These include VEGF, MMP-9, uPA/uPAR and tissue factor and
likely others yet to be discovered [5,32,33]. Because at least some of
these changes in gene expression occur downstream of signaling
events (e.g., ERK, Src), it is possible that these signals are responsible
for loss of syndecan-1 nuclear localization and resulting upregula-
tion of gene transcription.
Although heparan sulfates have been associated with several
functional roles within the nucleus, its inhibition of gene
transcription via inhibition of topoisomerase I and HAT activity
are particularly intriguing [15,17]. Regarding HATs, they regulate
gene expression by catalyzing acetylation of the N-terminal region
of histones, thereby modifying chromatin structure in a manner
that facilitates transcriptional activation [18]. It was recently
shown that both heparin and heparan sulfate can act as potent
inhibitors of p300 and pCAF HAT activities [17]. Addition of
heparin to pulmonary fibroblasts reduced histone H3 acetylation
by 50% and Chinese hamster ovary cells deficient in glycosami-
noglycan synthesis exhibited increased levels of acetylated histone
H3 when compared to controls. The reduction in nuclear
syndecan-1 that we detected following upregulation of heparanase
expression thus could lead to increased histone acetylation with an
associated increase in gene transcription.
We and others have speculated that heparanase acts as a master
regulator of the aggressive tumor phenotype [2,5]. This apparently
is accomplished via heparanase effects on multiple cell behaviors
including gene expression. Our findings indicate that heparanase
regulation of gene expression may be related to its ability to inhibit
accumulation of heparan sulfate proteoglycans within the nucleus.
Thus, strategies to enhance nuclear heparan sulfate levels may
prove effective in blocking at least some of the heparanase-
mediated effects that promote tumor growth and metastasis.
Materials and Methods
Cells and transfections
CAG cells were isolated from a myeloma patient as previously
described [19]. The cells were obtained and utilized following
signed informed consent, in accordance with the Declaration of
Helsinki. CAG cells with modified levels of heparanase expression
have been previously extensively characterized [3,5,21] and
include i) heparanase-low (HPSE-low) cells prepared by transfec-
tion with empty vector, ii) heparanase high (HPSE-high) cells
prepared by transfection with vector containing the cDNA for
human heparanase, iii) cells transduced with viral vectors
containing a control shRNA sequence, and iv) cells transduced
with viral vectors containing a shRNA sequence to knockdown
heparanase expression.
Treatment of cells with recombinant heparanase
Recombinant heparanase (kindly provided by Dr. Israel
Vlodavsky and prepared as described [34]) at doses of 0.1, 1.0,
10 or 50 ng/ml was added to 6610
6 cells in 6 ml of complete
RPMI medium, with a repeated addition of the same dose of
heparanase 12 h later. 24 h after the initial dose of heparanase,
cells and their conditioned medium were harvested. 1610
6 cells
were used for analysis of cell surface expression of syndecan-1 by
flow cytometry, and the remaining cells were used for preparation
of nuclear and non-nuclear extracts.
Preparation of nuclear and non-nuclear fractions
Nuclear and non-nuclear fractions were prepared as previously
described [35]. 6610
6 cells were washed with cold PBS,
Figure 4. Exogenous recombinant heparanase (rHPSE) de-
creases nuclear syndecan-1 levels in a concentration-depen-
dent manner. Recombinant heparanase was added to CAG cells
having very low levels of heparanase expression (shRNA knockdown
cells). Nuclear and non-nuclear fractions were prepared and syndecan-1
levels analyzed by A) western blotting and B) ELISA. Grey bars=non-
nuclear fraction; Black bars=nuclear fraction. Error bars represent
standard error of the mean. *, P,0.01 vs. nuclear syndecan-1 in cells
treated with 0 ng/ml rHPSE.
doi:10.1371/journal.pone.0004947.g004
Nuclear Syndecan-1
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suspended in 0.5 ml of lysis buffer (10 mM Tris HCl, pH 7.4,
10 mM NaCl, 3 mM MgCl2, 0.5% NP40, 0.56 M Sucrose, and
protease inhibitor cocktail). Cells were immediately dounced
exactly 10 times in a small homogenizer (2 ml Kontes homoge-
nizer, pestle overall6shaft O.D.(mm): 160650, tube overall6re-
servoir O.D.(mm): 100630). The lysate was transferred into a
microcentrifuge tube, incubated on ice for 10 minutes and the cell
lysate spun down at 3000 RPM at 4uC for 5 minutes. The
supernatant represents the non-nuclear fraction and was trans-
ferred to another tube. The pellet was washed with 200 mlo f
hypotonic buffer (10 mM Hepes pH 7.9, 1.5 mM MgCl2,1 0m M
KCl, and protease inhibitor cocktail) and centrifuged at 6000
RPM, 4uC for 5 minutes. The pellet was suspended in 100 mlo f
nuclear extraction buffer (20 mM Hepes pH 7.9, 20% glycerol,
600 mM KCl, 1.5 mM MgCl2, 0.2 mM EDTA, and protease
inhibitor cocktail) and refrigerated at 280uC for 1 h. The extracts
were thawed on ice, rotated at 4uC for 30 minutes and centrifuged
at 14,000 RPM for 30 minutes. The supernatant (nuclear extract)
was transferred to another tube, and stored at 280uC. For
normalization, equal amounts of protein from the two fractions (as
determined by BCA assay) were loaded for western blotting and
ELISA.
Western blots
For immunoblotting of syndecan-1, the extracts of nuclear and
non-nuclear fractions were separated on 4% ,15% gradient SDS-
PAGE, transferred onto Nytran
+ filters (Whatman/Schlei-
cher&Schuell, Florham Park, NJ), probed with antibody B-A38
(1:000; Cell Sciences, Inc., Norwood, MA) followed by a
horseradish peroxidase–conjugated secondary anti-mouse anti-
body (1:3000; GE Healthcare, Pittsburgh, PA), and visualized by
chemiluminescence (GE Healthcare, Pittsburgh, PA). For immu-
noblotting of heparanase, SP1 or actin, the cell extracts were
separated on 10% SDS-PAGE, transferred onto nitrocellulose
filters (Whatman/Schleicher&Schuell), probed with anti-hepar-
anase (1:000; [21]), anti-SP1 (1:1000, Santa Cruz Biotechnology,
Santa Cruz, CA) or anti-actin (1:500, Santa Cruz Biotechnology)
antibodies, followed by a horseradish peroxidase–conjugated
secondary antibody (1:3000; GE Healthcare), and visualized by
chemiluminescence. For western blots, data shown are represen-
tative blots from a minimum of three independent experiments.
Enzyme-linked immunosorbent assay (ELISA)
The levels of syndecan-1 present in 2.5 mg of protein from each
fraction were measured by an Eli-pair kit from Diaclone (Cell
Sciences, Inc.). The syndecan-1 content was calculated as the
number of nanograms of syndecan-1 in each microgram of total
protein in cell extracts or the number of nanograms of syndecan-1
in each milliliter of conditioned medium. The ELISA data shown
are from two separate experiments with duplicate wells for each
experimental point. Thus, each bar represents four independent
determinations.
Immunocytochemistry
Cells were fixed with 3% formaldehyde in PBS for 45 min at
room temperature. 70 ul of cell suspension was loaded into the
cytospin funnel and spun onto a slide at 1000 RPM for 5 min. The
cells on the slides were postfixed with 3% formaldehyde in PBS for
5 min. Cells were permeablized with 0.5% Triton X-100 in PBS
for 3 min at room temperature and rinsed in PBS with 3 quick
changes. The slides were incubated with 1% BSA in PBS for
30 min at room temperature followed by incubation with FITC-
conjugated or unconjugated B-A38 (1:20 in 1% BSA in PBS) at
4uC overnight followed by room temperature for 2 h. After
washing, the cells incubated with unconjugated B-A38 were
further incubated with antimouse IgG-Alexa 594 (1:100; Invitro-
gen, Carlsbad, CA) in 1% BSA in PBS for at room temperature
1 h. After washing in PBS, cells were stained with Hoechst 33258
(Invitrogen) at 20 mg/ml in PBS for 4 min to label nuclei. Cells
were viewed and photographed using confocal laser microscopy.
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